We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Surgical Versus Medical Treatment of Acromegaly

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01000090
First Posted: October 22, 2009
Last Update Posted: December 3, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
University of Aarhus
  Purpose

Evaluate biochemical differences in acromegalic patients treated with surgery versus somatostatin analogues (SMS) (after surgery or alone).

Hypothesis: Treatment modality exhibit different biochemical responses in acromegaly.


Condition
Acromegaly

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Surgical Versus Medical Treatment of Acromegaly: Effects on Biochemical Markers

Resource links provided by NLM:


Further study details as provided by University of Aarhus:

Biospecimen Retention:   Samples Without DNA
Serum

Enrollment: 63
Study Start Date: October 2009
Study Completion Date: June 2011
Primary Completion Date: February 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
Acromegaly patients, somatostain analogues
Acromegaly patients, surgery

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Acromegalic patients followed in the outpatient clinic at Århus University Hospital, Medical Department M
Criteria

Inclusion Criteria:

  • Acromegaly diagnosis
  • treated with Somatostatin analogues or surgery
  • in treatment control

Exclusion Criteria:

  • treatment with GH-antagonist
  • never treated
  • not in treatment control
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01000090


Locations
Denmark
Århus University Hospital, Medical department M
Århus, Denmark, 8000
Sponsors and Collaborators
University of Aarhus
Investigators
Study Director: Kristine Z Rubeck, stud. med. Medical department M, Århus University Hospital
Principal Investigator: Jens Otto L Jørgensen, MD Medical department M, Århus University Hospital
Study Director: Michael Madsen, MD Medical department M, Århus University Hospital
Study Director: Sanne Fisker, MD Medical department M, Århus University Hospital
Study Director: Caroline Adreasen, MD Medical department M, Århus University Hospital
Study Director: Jan Frystyk, MD Medical department M, Århus University Hospital
  More Information

Responsible Party: University of Aarhus
ClinicalTrials.gov Identifier: NCT01000090     History of Changes
Other Study ID Numbers: kzr200809
First Submitted: October 21, 2009
First Posted: October 22, 2009
Last Update Posted: December 3, 2015
Last Verified: June 2011

Keywords provided by University of Aarhus:
Acromegaly
Somatostatin analogues
Treatment

Additional relevant MeSH terms:
Acromegaly
Bone Diseases, Endocrine
Bone Diseases
Musculoskeletal Diseases
Hyperpituitarism
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Endocrine System Diseases